Compare TNXP & EVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TNXP | EVI |
|---|---|---|
| Founded | 2007 | 1959 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Consumer Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 192.9M | 204.6M |
| IPO Year | 2008 | 1995 |
| Metric | TNXP | EVI |
|---|---|---|
| Price | $12.32 | $15.75 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $35.00 |
| AVG Volume (30 Days) | ★ 567.5K | 80.3K |
| Earning Date | 05-11-2026 | 05-15-2026 |
| Dividend Yield | N/A | ★ 1.81% |
| EPS Growth | ★ 91.75 | 32.43 |
| EPS | N/A | ★ 0.31 |
| Revenue | $13,107,000.00 | ★ $389,830,000.00 |
| Revenue This Year | $558.11 | $15.53 |
| Revenue Next Year | $38.29 | $3.83 |
| P/E Ratio | ★ N/A | $51.90 |
| Revenue Growth | ★ 29.85 | 10.26 |
| 52 Week Low | $10.03 | $14.06 |
| 52 Week High | $69.65 | $34.82 |
| Indicator | TNXP | EVI |
|---|---|---|
| Relative Strength Index (RSI) | 49.93 | 48.26 |
| Support Level | $12.08 | $15.61 |
| Resistance Level | $13.17 | $21.36 |
| Average True Range (ATR) | 0.87 | 0.87 |
| MACD | 0.15 | 0.05 |
| Stochastic Oscillator | 61.08 | 61.70 |
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
EVI Industries Inc is a value-added distributor and service provider in the commercial laundry industry. It sells and leases commercial laundry equipment, specializing in washing, drying, finishing, material handling, water heating, power generation, and water reuse applications. The company supports its equipment offerings with installation, maintenance, and repair services through a large network of trained technicians. It serves a wide range of customers, including commercial, industrial, institutional, government, and retail sectors. Geographically, the company serves various countries including United States, Canada, the Caribbean, and Latin America.